How big is ATAI Life Sciences NV?

As of Jun 18, ATAI Life Sciences NV has a market capitalization of 445.67 million, with net sales of 1.87 million and a net profit of -137.53 million over the latest four quarters. The company reported shareholder's funds of 116.30 million and total assets of 159.39 million as of Dec 24.

Market Cap: As of Jun 18, ATAI Life Sciences NV has a market capitalization of 445.67 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, ATAI Life Sciences NV reported net sales of 1.87 million and a net profit of -137.53 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 116.30 million and total assets of 159.39 million.

What does ATAI Life Sciences NV do?

ATAI Life Sciences NV is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $2 million and a net loss of $26 million as of March 2025, with a market cap of $445.67 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -63.76%.

Overview: <BR>ATAI Life Sciences NV operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -26 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 445.67 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.54 <BR>Return on Equity: -63.76% <BR>Price to Book: 2.93<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold ATAI Life Sciences NV?

Is ATAI Life Sciences NV overvalued or undervalued?

As of May 14, 2025, ATAI Life Sciences NV is considered risky due to overvaluation indicated by a price-to-book ratio of 3.18, an EV to EBITDA of -4.41, and a negative ROCE of -130.41%, despite a strong year-to-date stock performance of 254.89%.

As of 14 May 2025, ATAI Life Sciences NV has moved from a grade of does not qualify to risky. The company appears to be overvalued given its current financial metrics. The price-to-book value stands at 3.18, while the EV to EBITDA ratio is an alarming -4.41, and the return on capital employed (ROCE) is significantly negative at -130.41%. <BR><BR>In comparison to peers, such as Praxis Precision Medicines, Inc., which has a P/E ratio of -3.42 and an EV to EBITDA of -2.05, ATAI's valuation ratios indicate a concerning position within the industry. The stock has performed exceptionally well recently, with a year-to-date return of 254.89% compared to the S&P 500's 12.22%, suggesting strong market interest despite the underlying financial risks.

Is ATAI Life Sciences NV technically bullish or bearish?

As of October 10, 2025, ATAI Life Sciences NV shows a mildly bullish trend with positive momentum from MACD and Bollinger Bands, despite bearish RSI signals, and has significantly outperformed the S&P 500 year-to-date with a return of 306.02%.

As of 10 October 2025, the technical trend for ATAI Life Sciences NV has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is also bullish, indicating positive momentum. However, the RSI shows a bearish stance on both the weekly and monthly charts, suggesting potential weakness. The Bollinger Bands are mildly bullish on both time frames, and the daily moving averages are bullish, supporting a positive short-term outlook. The KST is bullish on both weekly and monthly charts, but Dow Theory indicates a mildly bearish trend on the weekly, with no trend on the monthly.<BR><BR>In terms of performance, ATAI Life Sciences has significantly outperformed the S&P 500 year-to-date with a return of 306.02% compared to the S&P 500's 11.41%. Over the past year, ATAI has returned 390.91%, while the S&P 500 returned 13.36%. Overall, the current technical stance is mildly bullish, driven by the mixed indicators across different time frames.